Rituximab treatment of adults with primary focal segmental glomerulosclerosis
- Resource Type
- article
- Authors
- Liuwei Wang; Lu Yu; Yulin Wang; Yanhong Guo; Zihan Zhai; Lin Tang
- Source
- Scientific Reports, Vol 13, Iss 1, Pp 1-6 (2023)
- Subject
- Medicine
Science
- Language
- English
- ISSN
- 2045-2322
Abstract To evaluate the efficacy and safety of rituximab (RTX) in the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults. The clinical data of patients with primary FSGS who received RTX treatment in the First Affiliated Hospital of Zhengzhou University were analyzed retrospectively. The selected patients received RTX twice or four times, with a single dose of 375 mg/m2, and the interval between two times of administration of RTX was 2–4 weeks. The treatment target is to achieve the clearance of B cells (peripheral blood B cell count